Predictors of survival in patients with bone metastasis of lung cancer
Predictors of survival in patients with bone metastasis of lung cancer
复制标题
DOI：
10.1007/s11999-007-0051-0
复制
发表时间：
2008-03-01
影响因子：
4.2
通讯作者：
Mitsudomi, Tetsuya
中科院分区：
文献类型：
--
作者：
Sugiura, Hideshi;Yamada, Kenji;Mitsudomi, Tetsuya
肺癌骨转移患者的预后还没有很好的文献记载。我们对118例肺癌骨转移患者的骨转移后生存率和预后因素进行了评估。肺癌骨转移后6个月、1年、2年的累积生存率分别为59.9%、31.6%、11.3%。中位生存期9.7个月(中位数7.2个月；范围0.1~74.5个月)。女性和腺癌、孤立性骨转移、无附件骨转移、无病理性骨折、功能状态1或更低、使用全身化疗和使用上皮生长因子受体抑制剂的患者预后较好。对单变量和多变量的分析表明，腺癌患者预后较好，无附件骨转移的证据，并接受上皮生长因子受体抑制剂治疗。在接受上皮生长因子受体抑制剂治疗的小组中，平均生存期比较大的未治疗组更长。这些数据初步表明，使用上皮生长因子受体抑制剂治疗可能会提高骨转移后的存活率。
The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.